Inception Growth Acquisition Limited - Rights Stock (NASDAQ: IGTAR)

Latest news for Inception Growth Acquisition Limited - Rights (NASDAQ:IGTAR) Stock

Inception Growth Acquisition Limited - Rights

WIIM

SOAR

Volato Group shares are trading higher. The stock may be rising on continued strength after the company recently reported a year-over-year increase in Q3 financial results.

<a href="https://www.benzinga.com/digital-assets/livestream" title="https://www.benzinga.com/digital-assets/livestream">https://www.benzinga.com/digital-assets/livestream</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Events

Exclusives

Markets

$BTC

Anthony Dixon, Digital Assets Product Manager, FTSE Russell / LSEG Says Looking Forward, I Think We Can See Some More Elaborate Products In The Crypto Space

Zach Pandl, Managing Director, Research, Grayscale Investments Says Macro Case: The High Inflation, Legacy Of Government Debt, Fragmenting International Monetary System Are What Drives People To Bitcoin

IBRX

ImmunityBio shares are trading higher after the company announced the completion of ANKTIVA's post-approval enrollment of the 100th patient in the BCG unresponsive NMIBC CIS trial. Additionally, D. Boral Capital maintained a Buy rating on the stock.

Interview

Franklin Templeton Research Analyst David Alderman Says Imagines Stablecoins Will Be More Active, Institutional Investors Will Have Easier Access To The Different Types Of Crypto Products They Want

FUTU

Futu Holdings shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results. Also, Citigroup downgraded the stock from Buy to Neutral.

DTCC Digital Assets Executive Director Jennifer O'Rourke Says Just Because Bill Is Passed Into Law Does Not Mean It Is Ready To Go Compliance Wise, There Are Other Procedural Things That Need To Happen Afterwards Including Rule And Commentary Process, Harmonization Between Agencies, Need To Have Deeper Education And Adoption Process By The Market Participants

On Monday, Silence Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42046710/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-2024-american-heart-associa" rel="noreferrer noopener">levels (≥125 nmol/L)</a>.
These data were presented at the American Heart Association (AHA) Scientific Sessions.
Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks.
This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluate the effects of treatment over time, including intervals between doses.
Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted, and no safety concerns emerged with infrequent dosing.
William Blair notes that while Silence's data shows the drug effectively lowers Lp(a) levels, the Q24W dosing schedule may not be competitive. This is due to a decline in Lp(a) reduction between doses.
This dosing schedule could be an option for maintenance after stable Lp(a) reductions are reached. However, the analyst expects more frequent dosing, possibly every three months, to be needed. This may reduce zerlasiran's competitive edge compared to Amgen Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) olpasiran.
The analyst writes, "Silence continues to execute on both the zerlasiran and divesiran lead clinical programs. While data for zerlasiran presented at AHA show that zerlasiran is an efficacious Lp(a) lowering agent over 48 weeks with Q24W dosing, we are incrementally negative on zerlasiran's competitive profile given the waning of Lp(a) lowering between the infrequent doses, which has not been demonstrated with olpasiran at a once-quarterly dosing frequency."
Price Action: SLN stock is down 33.80% at $7.20 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Aclaris </a><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments</a></li>
</ul>

Analyst Color

Biotech

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

AMGN

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Analysts expect Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) to report third-quarter revenue of $25.9 billion when the company reports third-quarter financial results on Wednesday, Nov. 20 <a href="https://www.benzinga.com/earnings">before the market opens.</a>
 That&#8217;s up from $25.4 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The Minneapolis-based company has beaten analyst estimates for revenue in six of the last eight quarters and seven of the last 10 quarters overall.
Analysts expect Target to report third-quarter earnings per share of $2.30 — up from $2.10 in last year's third quarter. The company has beaten analyst estimates in six of the last seven quarters and six of the last 10 quarters overall.
<a href="https://www.benzinga.com/news/earnings/24/08/40482203/target-q2-earnings-revenue-and-profit-beat-digital-sales-boost-annual-profit-outlook-hiked">Guidance from Target </a>calls for third-quarter comparable sales to be up 0% to 2% year-over-year. The company also guided for third-quarter earnings per share to be in the range of $2.10 to $2.40.
Target raised its full-year guidance after second-quarter results with earnings per share of $9.00 to $9.70 now expected, up from a prior range of $8.60 to $9.60.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42068978/how-to-earn-500-a-month-from-target-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings</a>
<h3 class="wp-block-heading">Key Items to Watch</h3>
Target visitor traffic was up 1% year-over-year, per data from Placer.ai. It outpaced retail rival Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), which had 0.9% visitor growth year-over-year.
The Placer.ai <a href="https://www.placer.ai/blog/superstores-and-wholesale-clubs-ahead-of-the-holidays">report</a> also sheds some light on upcoming trends to watch for Target and how the company's guidance could factor into the holiday season. Target saw the biggest weekly holiday visits boost of the tracked retail chains, with foot traffic up 87.3% the week before Christmas compared to the company's weekly average. 
Walmart, by comparison, saw a 39.6% increase in its weekly average visitors for the week before Christmas last year.
"Digging deeper into historical data suggests that it is Target that is primed to experience the busiest holiday season of the analyzed chains," Placer.ai said.
Target also saw the biggest spike of the tracked retailers for the weekly visitor growth for the week of Turkey Wednesday and Black Friday, with visits up 18.9% compared to the company's weekly average.
"With recent visits to Target on par with — or slightly above — last year's levels, the retail giant is likely poised to win the holidays once again."
Along with guidance and commentary on the holiday shopping season, another area to watch in Target's report will be same-day delivery services. The company reported a double-digit increase in this segment in the second quarter.
Sales by segment could also be an area to watch with Target saying apparel and discretionary sales were strong in the second quarter.
Target's quarterly results come one day after Walmart <a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast">reported third-quarter results</a>. Walmart reported revenue and earnings per share that came in ahead of Street consensus estimates. The retailers also raised its guidance.
The strong quarterly report from Walmart could be a positive for Target heading into the earnings report as it could signal the strength of the American consumer. The key will be making sure that Walmart didn't end up taking market share away from Target as a result.
Price Action: Target stock is down 1% to $155.37 on Tuesday versus a 52-week trading range of $128.37 to $181.86. Target stock is up 8.6% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41338328/taylor-swift-teams-up-with-target-for-exclusive-black-friday-merch-will-swifties-boost-q4-s">Taylor Swift Teams Up With Target For Exclusive Black Friday Merch: Will Swifties Boost Q4 Sales, Prove Donald Trump Wrong?</a></li>
</ul>
Image: Shutterstock

Previews

Target Q3 Earnings Preview: Analysts Expect Revenue, EPS Growth As Attention Turns To Holiday Quarter

Investors with a lot of money to spend have taken a bearish stance on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for CVS Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 61%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $668,128, and 6 are calls, for a total amount of $310,421.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $80.0 for CVS Health over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CVS Health options trades today is 1767.3 with a total volume of 21,448.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CVS Health's big money trades within a strike price range of $50.0 to $80.0 over the last 30 days.
<h3>CVS Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732048235_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$1.27</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$56.00</td>
<td>$219.5K</td>
<td>594</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.25</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$56.00</td>
<td>$141.0K</td>
<td>594</td>
<td>3.3K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.0</td>
<td>$0.98</td>
<td>$0.99</td>
<td>$54.00</td>
<td>$106.4K</td>
<td>57</td>
<td>1.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$0.95</td>
<td>$0.94</td>
<td>$0.95</td>
<td>$56.00</td>
<td>$86.6K</td>
<td>527</td>
<td>919</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$60.00</td>
<td>$72.8K</td>
<td>10.4K</td>
<td>960</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 6,498,681, the price of CVS is down by -0.72%, reaching $55.65.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Expert Opinions on CVS Health</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $65.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Mizuho has decided to maintain their Outperform rating on CVS Health, which currently sits at a price target of $66. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for CVS Health, targeting a price of $60. 
&#x2A; An analyst from UBS persists with their Neutral rating on CVS Health, maintaining a target price of $62. 
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $71. 
&#x2A; In a positive move, an analyst from Wells Fargo has upgraded their rating to Overweight and adjusted the price target to $66. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

CVS Health Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RBLX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Roblox.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 33%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $259,440, and 10 are calls, for a total amount of $562,301.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $80.0 for Roblox during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Roblox stands at 3636.38, with a total volume reaching 16,256.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Roblox, situated within the strike price corridor from $40.0 to $80.0, throughout the last 30 days.
<h3>Roblox Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732048230_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$111.3K</td>
<td>12.4K</td>
<td>2.6K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$48.00</td>
<td>$79.0K</td>
<td>12.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$73.1K</td>
<td>12.4K</td>
<td>2.2K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$48.00</td>
<td>$63.5K</td>
<td>12.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RBLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$50.00</td>
<td>$62.7K</td>
<td>11</td>
<td>172</td>
</tr>
</tbody>
</table>

<h3>About Roblox</h3>
Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.
In light of the recent options history for Roblox, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Roblox</h3>
<ul>
<li>With a volume of 4,103,597, the price of RBLX is up 2.78% at $52.45. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Expert Opinions on Roblox</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $56.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Roblox, maintaining a target price of $55. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Roblox, maintaining a target price of $58. 
&#x2A; Consistent in their evaluation, an analyst from Benchmark keeps a Buy rating on Roblox with a target price of $60. 
&#x2A; An analyst from Macquarie persists with their Outperform rating on Roblox, maintaining a target price of $58. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $49. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Roblox, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

RBLX

Roblox Unusual Options Activity For November 19

Deep-pocketed investors have adopted a bullish approach towards Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CCJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Cameco. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 77% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $529,500, and 20 are calls, amounting to $1,480,442.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $70.0 for Cameco during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Cameco stands at 8976.08, with a total volume reaching 33,251.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cameco, situated within the strike price corridor from $20.0 to $70.0, throughout the last 30 days.
<h3>Cameco Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732048226_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.76</td>
<td>$2.72</td>
<td>$2.73</td>
<td>$55.00</td>
<td>$409.5K</td>
<td>3.4K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.7</td>
<td>$4.6</td>
<td>$4.63</td>
<td>$55.00</td>
<td>$209.7K</td>
<td>13.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.38</td>
<td>$0.34</td>
<td>$0.34</td>
<td>$70.00</td>
<td>$195.3K</td>
<td>4.8K</td>
<td>5.7K</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$0.3</td>
<td>$0.15</td>
<td>$0.24</td>
<td>$53.00</td>
<td>$120.0K</td>
<td>5.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.26</td>
<td>$2.24</td>
<td>$2.25</td>
<td>$60.00</td>
<td>$109.8K</td>
<td>38.3K</td>
<td>4.2K</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
<h3>Where Is Cameco Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,893,171, with CCJ's price up by 2.33%, positioned at $57.2.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 79 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cameco options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With CCJ

Regarding retirement planning, an annuity can feel like a <a href="https://www.benzinga.com/personal-finance/24/11/41918104/are-you-on-track-to-retire-rich-heres-the-nest-egg-you-need-to-be-considered-a-wealthy-retiree">comforting safety net</a>. You trade a chunk of your savings – say $250,000 – for a steady income stream, often for the rest of your life. But how much bang for your buck are you getting? Let's break it down.
Why Buy an Annuity in the First Place?
Annuities are for people who like the idea of guaranteed income. Think of it as creating your pension. You hand over a pile of money to an insurance company and they promise to pay you back in regular installments. It's a way for retirees to take the stress out of budgeting, knowing you'll have money coming in no matter what. But like any financial product, annuities have pros, cons and fine print.
What You Can Expect from a $250,000 Annuity
The <a href="https://www.benzinga.com/personal-finance/24/09/40739486/if-i-buy-a-100-000-annuity-how-much-cash-will-it-pay-me-each-month">income from an annuity</a> depends on factors like age, gender and whether you're buying it for yourself or as a joint annuity with a spouse. Your state also impacts because some places have specific insurance regulations, such as a guaranteed minimum interest rate.&nbsp;
Here's what $250,000 could get you using annuity calculators with rates for November 2024.&nbsp;
Immediate Annuity Payouts
These start payments immediately, perfect if you're ready to retire now.
At Age 65:
<ul>
<li>Male: About $1,572 per month</li>
<li>Female: About $1,498 per month</li>
<li>Joint Life (both 65): About $1,354 per month</li>
</ul>
At Age 70:
<ul>
<li>Male: About $1,776 per month</li>
<li>Female: About $1,674 per month</li>
<li>Joint Life (both 70): About $1,482 per month</li>
</ul>
At Age 75:
<ul>
<li>Male: About $2,084 per month</li>
<li>Female: About $1,933 per month</li>
<li>Joint Life (both 75): About $1,663 per month</li>
</ul>
The older you are when payments begin, the higher your monthly payout. Why? Fewer years of payments for the insurer to cover. You probably also noticed men receive slightly more than women due to the difference in life expectancy.&nbsp;
Deferred Annuity Payouts
If you're not in a rush, deferred annuities can be better. Letting your money sit and grow for a while will lock in higher monthly payments when the payouts eventually start. How much higher? That depends on the length of the deferral period and interest rates at the time.
Variable Annuities
Looking for a little excitement (Or stress)? Variable annuities tie your income to the stock market. If your investments do well, you could receive more money. But if the market dips, so could your payout. It's a gamble that's not for everyone.
Common Questions About Annuities
Can I pull out extra money if I need it?
Sometimes. Many annuities let you make extra withdrawals, but doing so can reduce your future payments.
What happens if I die?
It depends on the payout option you choose. Some plans offer "Life with Period Certain," which guarantees payments to your beneficiary for several years even if you pass away early.
Can annuity payments grow with inflation?
Some annuities offer a cost-of-living adjustment (COLA). This is great for keeping up with inflation but lowers your starting payment.
Are payments taxed?
Yes, but only the earnings portion. Part of each payment is considered a return of your initial investment and isn't taxed. The rest, representing growth, is taxed as ordinary income unless held in a tax-advantaged account.
Should You Buy an Annuity?
Annuities aren't one-size-fits-all. They're a great way to ensure a steady income stream, but they come with trade-offs – like losing liquidity and potential growth in the stock market. Before diving in, closely examine your finances and retirement goals.
Annuities are complicated. <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">Consulting with a financial advisor</a> can help you decide if this safety net is worth your $250,000 or if there's a better option to generate income for you.&nbsp;

Personal Finance

I Want To Buy A $250,000 Annuity – What's The Monthly Income It'll Bring In?

On Monday, Aclaris Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia" rel="noreferrer noopener">both TSLP and IL4R</a>.
In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ), targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Under the terms of the agreement, Biosion shall receive over&nbsp;$40 million&nbsp;cash payment as an upfront license fee and reimbursement for certain development costs &amp; drug product materials.
Biosion shall also receive 19.9% shares of Aclaris Therapeutics.
Additional regulatory and sales milestone payments exceed&nbsp;$900 million, with tiered low-to-mid single-digit royalty payments based on a percentage of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42036056/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-fi" rel="noreferrer noopener">annual net sales</a>.
Leerink Partners upgraded Aclaris from Market Perform to Outperform, with a price target of $7, <a target="_blank" href="https://www.benzinga.com/quote/ACRS/analyst-ratings" rel="noreferrer noopener">up from $2</a>.
The analyst writes, &#8220;Following completion of their strategic review, we expect investor focus to shift to ACRS&#8217; newly strengthened immunology-focused pipeline.&#8221;
Leerink writes that these updates mark a fresh start for Aclaris Therapeutics, with a clear strategic direction and promising catalysts in the next 6-12 months. This progress could reduce risks for BSI-045B and significantly enhance its value.
The analyst has updated the model to include BSI-045 B&#8217;s potential in atopic dermatitis (AD), estimating around $1.3 billion in revenue by 2035 with a 35% probability of success. The analyst also anticipates multiple Phase 2 trial results from China in asthma and chronic rhinosinusitis with nasal polyps, which could provide more insight into BSI-045 B&#8217;s potential.
Additionally, Leerink expects further progress in de-risking the company&#8217;s pipeline in the first half of next year.
BTIG upgrades Aclaris Therapeutics from Neutral to Buy and announces a $8 price target.
Price Action: ACRS stock is up 55.60% at $4.88 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42063475/interactive-strength-shares-jumps-premarket-as-saudi-fitness-chain-adopts-clmbr-machines" target="_blank" rel="noreferrer noopener">Interactive Strength Shares Jump As Saudi Fitness Chain Adopts CLMBR Machines: Details</a></li>
</ul>

Upgrades

Contracts

ACRS

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

<a href="https://www.benzinga.com/fintech-awards/livestream" title="https://www.benzinga.com/fintech-awards/livestream">https://www.benzinga.com/fintech-awards/livestream</a>

GTN CEO, Americas Eric Krueger Says 90% Percent Of Trading Volume Is Into U.S. Market; As Long As U.S. Continues To Outperform, We Will See Massive Inflow Of Foreign Retail Investors

The retail investing landscape is changing as individuals are increasingly looking to take on more risk. Yoni Assia, co-founder and CEO of investing platform eToro, believes crypto is playing a big role in the <a href="https://www.benzinga.com/money/retail-investors-ve-institutional-investors">evolution of the retail investor</a>.
What To Know: Tuesday at the <a href="https://www.benzinga.com/fintech-awards?__hstc=28787939.5f6980ec6f37192ae95c332ee656a790.1732029557803.1732029557803.1732029557803.1&amp;__hssc=28787939.1.1732029557803&amp;__hsfp=3317113319">Benzinga Fintech Deal Day &amp; Awards</a>, Assia made the case that risk appetite is the biggest difference between older generations and retail investors today.
Older generations focused on dividend yields, the Baby Boomers started focusing on price-to-earnings multiples, Gen X began focusing more on growth, Millennials took it a step further and focused on tech stocks and now Gen Z is more focused on crypto and things like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) becoming the currency of Mars, he said.
EToro started the year with just 2% of its customers trading crypto and now has more than 90% of customers involved with crypto in some capacity across its platform, Assia said.
Crypto is driving that bigger tolerance for risk due to its becoming a &#8220;generational asset class&#8221; and a &#8220;gateway trade&#8221; for a lot of individual investors. Many retail investors come to the platform to trade Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), for example, and then end up exploring other investment options, he said.
Many crypto investors have a higher appetite for risk and as crypto investors cross into traditional markets, retail traders are starting to make a bigger splash. The surge in retail investors in recent years has changed market dynamics, Assia explained.
Check This Out: <a href="https://www.benzinga.com/news/events/24/11/42071064/exclusive-anthony-pompliano-calls-for-us-to-buy-250b-bitcoin-on-day-1-of-trump-administration-protect-our-future-its-such-a-no-brainer">EXCLUSIVE: Anthony Pompliano Calls For US To Buy $250B Bitcoin On Day 1 Of Trump Administration: &#8216;Protect Our Future, It&#8217;s Such A No Brainer&#8217;</a>
The way investors get information has also changed. In the past, a lot of individuals would read investment reports and put a lot of time into researching a potential investment, but now traders are getting information very quickly from various news outlets and from other individual investors on social media platforms like Reddit and X. If they are reading research reports, they are likely using ChatGPT or another LLM to pull the key information, he added.
When talking about retail investors versus individual investors, you often hear the terms &#8220;dumb money&#8221; and &#8220;smart money,&#8221; but &#8220;I think that&#8217;s completely wrong,&#8221; Assia said: &#8220;We see it on our platform.&#8221;
eToro allows investors to see what other investors on the platform are doing and even copy their trades. Assia told the crowd at the Benzinga conference that there are 3,200 investors on the platform that are being copied by other traders. Most of those investors consistently generate double-digit returns and often outpace the S&amp;P 500. 
&#8220;These are like hedge-fund level returns of our top retail investors on the platform. I think this narrative is coming from the people who want to manage the retail&#8217;s money and don&#8217;t want them to manage their own money,&#8221; he said. 
The playing field is already in the process of being leveled and new AI tools are only going to help accelerate retail&#8217;s ability to see consistent success in the markets, Assia said. 
The <a href="https://www.benzinga.com/fintech-awards?__hstc=28787939.5f6980ec6f37192ae95c332ee656a790.1732029557803.1732029557803.1732029557803.1&amp;__hssc=28787939.1.1732029557803&amp;__hsfp=3317113319">Benzinga Fintech Deal Day &amp; Awards</a> panel was called &#8220;The Evolution of the Retail Investor&#8221; and was hosted by CoinDesk&#8217;s Benjamin Schiller.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42069891/sp-500-to-reach-6500-by-end-of-2025-analysts-predict-could-it-spark-ma-revival">S&amp;P 500 To Reach 6,500 By End Of 2025, Analysts Predict: Could It Spark M&amp;A Revival?</a></li>
</ul>
Photo: Shutterstock.

$DOGE

EXCLUSIVE: Retail Investors Are Taking On More Risk And Finding Success — Is Crypto Acting As A 'Gateway Trade?'

Cryptocurrency markets are trading higher, with Bitcoin recording a new all-time high at $94,040, according to Coingecko data. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$93,312.89</td>
<td>+2.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,122.39</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$243.76</td>
<td>+2.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.4053</td>
<td>+10%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002537&nbsp;&nbsp;</td>
<td>+4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 102.3% and daily active addresses up by 13%. Transactions greater than $100,000 are up from 8,261 to 11,812 in a single day. Exchanges netflows are down by 192%.</li>
<li>Coinglass data reports 98,554 traders were liquidated in the past 24 hours for $289.96 million. Open interest spiked to $59.3 billion.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42059827/crypto-exchange-gemini-launches-services-in-france-following-regulatory-approval">Crypto Exchange Gemini Launches Services In France Following Regulatory Approval</a></li>
<li><a href="https://www.benzinga.com/24/11/42069770/us-congress-could-set-the-stage-for-broader-crypto-adoption-says-digital-asset-leader">Crypto Growth Hinges On &#8216;Thoughtful Policy,&#8217; Clear Regulations, Says Expert</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069258/whats-going-on-with-bakkt-holdings-stock-tuesday">What&#8217;s Going On With Bakkt Holdings Stock Tuesday?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42055570/bitfinex-bitcoin-laundering-case-lands-crocodile-of-wall-street-in-jail">Bitfinex Bitcoin Laundering Case Lands &#8216;Crocodile Of Wall Street&#8217; In Jail</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42058823/blackrocks-spot-bitcoin-etf-to-open-for-options-trading-heres-why-it-could-be-a-big-deal-for-bitcoin">BlackRock&#8217;s Spot Bitcoin ETF To Open For Options Trading: Here&#8217;s Why It Could Be A Big Deal For Bitcoin</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>&nbsp;$0.00005573</td>
<td>+14%</td>
</tr>
<tr>
<td>Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>)</td>
<td>&nbsp;$0.1378</td>
<td>+13.5%</td>
</tr>
<tr>
<td>Goatseus Maximus (CRYPTO: GOAT)</td>
<td>&nbsp;$1.17&nbsp;</td>
<td>+12.8%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices crossing all-time highs of $94,000, crypto trader Jacob Canfield predicts a minimum target of $97,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> &#8211; A breakout fom our ascending triangle above here should give us a minimum target of $97,000. <a href="https://t.co/PLtKTWEmlz">pic.twitter.com/PLtKTWEmlz</a>
&mdash; Jacob Canfield (@JacobCanfield) <a href="https://twitter.com/JacobCanfield/status/1858928153185427592?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader More Crypto Online hopes that Bitcoin can move forward toward $95,000 and then maybe $97,000. On the other hand, the trader <a href="https://x.com/Morecryptoonl/status/1858936812082807069">remains</a> cautious suggesting this could be a corrective range. He believes the structure lacks clear direction and momentum and is therefore very fragile.
Santiment data noted that with Bitcoin peaking to all-time highs, whale transactions and retail FOMO could make the "short-term price action unpredictable, but the long-term indicators for Bitcoin looking quite sound."
It also added that in any long-term bull market, dormant coins continuously moving back into circulation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f973; Bitcoin has officially made a new all-time high, scraping as high as $93,850 on Coinbase at the time of this writing. Whale transactions and retail FOMO may make the short-term price action unpredictable, but the long-term indicators for BTC (and therefore, crypto) look quite… <a href="https://t.co/Ae5qtdU8QN">pic.twitter.com/Ae5qtdU8QN</a>
&mdash; Santiment (@santimentfeed) <a href="https://twitter.com/santimentfeed/status/1858942762206261428?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a></li>
</ul>
Image: Shutterstock

$BONK

$ETH

$HBAR

$SHIB

$SOL

Bitcoin Crosses $94,000 For New All-Time High, Dogecoin Back At $0.40, Ethereum Flat: 'Short-Term Price Action Unpredictable,' Say Analysts

Dividends

RGLD

Royal Gold Increases Annual Dividend From $1.60 To $1.80 Per Share

Franklin Templeton Research Analyst David Alderman Says There Are A Lot Of Crypto Protocols That Have Been Afraid To Add Some Sort Of Value Accrual Mechanism Or Utility To Token To Avoid Being Labeled As A Security,; Says People Are Hopeful About Where Regulatory Clarity Will Happen, Which Could Drive Growth In The US And Globally

TradeZero CEO And Co-Founder Daniel Pipitone Says [Next Main Street] Expanded Beyond Boarders; Folks Outside Country, Canada, Europe, Asia, Wanting To Trade

Comments

Inception Growth Acquisition Limited - Rights

News

Latest news for Inception Growth Acquisition Limited - Rights (NASDAQ:IGTAR) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga